#United States #Chicago #Patient Engagement #Vaniam Group #Alexandra Dubois

Enhancing Patient Engagement at Vaniam Group

On September 23, 2025, Vaniam Group announced a significant enhancement to its patient engagement strategy through the appointment of Alexandra Dubois as Senior Vice President of Patient Engagement. This strategic move highlights the company’s unwavering commitment to integrating genuine patient perspectives into its operations. Dubois’s involvement is expected to elevate the methodologies through which the firm connects with individuals affected by healthcare challenges.

Dubois’s role will involve close collaboration with Vaniam Group’s existing scientific and strategic leaders to bolster the company’s capabilities in patient engagement. The goal is clear: to ensure that the insights drawn from patients are woven into the decision-making processes at all organizational levels. This appointment marks a pivotal step in an ongoing strategy focused on deepening patient engagement initiatives, with plans for further development and expansion in the pipeline.

Deanna B. van Gestel, the Founder and CEO of Vaniam Group, emphasized the importance of this initiative, stating, “Our ability to bridge the gap between the biopharma community and patients relies on deeply understanding what matters most to those we serve. Alex's expertise and proven leadership will strengthen our ability to elevate patient voices.”

Dubois comes with a rich background of 25 years in both business-to-consumer and business-to-business fields. With over a decade of her career dedicated to patient engagement, she has established a commendable track record. Notably, she launched and led The Px Group—part of The CM Group—focusing on patient-centered strategies, which thrived under OPEN Health, its parent company.

At Vaniam Group, Dubois is set to take the helm in creating more impactful solutions that marry patient experiences with cutting-edge scientific knowledge. Her initiatives will aim to assist clients in identifying unmet patient needs, enhancing strategic responses, and driving innovation in healthcare. “Vaniam Group has built a reputation for transforming complex science into human connections,” Dubois remarked. She expressed her excitement in advancing an approach to patient engagement that not only amplifies voices of patients but also ensures their experiences shape advancements in oncology and rare disease treatment.

Vaniam Group’s approach is forward-thinking, as the company does not merely listen to patient feedback, but actively prioritizes these insights. By translating patient voices into actionable strategies, Vaniam Group helps biopharma innovators forge connections that yield significant and measurable outcomes within the healthcare arena. This fresh perspective ensures that patients are front and center in all dialogue surrounding their care and treatment solutions.

About Vaniam Group

Vaniam Group stands as a premier medical communications partner for innovative biopharma companies aiming to connect high-level science with human impact. By merging extensive scientific knowledge with actionable insights and innovative technology, the organization acts as a bridge between the medical community and the patients. It focuses on areas such as oncology, hematology, rare diseases, and immunology, further aiding in cultivating productive discussions and fostering collaborations that lead to breakthroughs in patient care.

To stay updated with how Vaniam Group is shaping the healthcare landscape, please visit vaniamgroup.com for more information.